Exelixis, Inc. (EXEL) - Q3 2007 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 28, 2007. Exelixis, Inc. is a biopharmaceutical company focused on discovering and developing small molecule therapies for cancer and other serious diseases. The company operates primarily through internal drug discovery and development, supplemented by strategic collaborations with major pharmaceutical partners. A significant portion of its clinical pipeline (compounds XL647, XL784, and XL999) is currently out-licensed to Symphony Evolution, Inc. (SEI), a variable interest entity consolidated by Exelixis.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 28, 2007 | Nine Months Ended Sep 28, 2007 |
|---|---|---|
| Total Revenues | $26,825 | $84,220 |
| Net Loss | $(13,696) | $(66,459) |
| Net Loss Per Share (Basic/Diluted) | $(0.14) | $(0.68) |
| Cash and Cash Equivalents | $141,326 (Balance Sheet) | $141,326 (Balance Sheet) |
| Total Liquidity (Cash + Marketable Securities) | $237,291 | $237,291 |
| Working Capital | $173,542 | $173,542 |
| Total Debt (Notes + Convertible Loans) | $112,368 | $112,368 |
| Operating Cash Flow (9 Months) | $(43,825) | $(43,825) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 14% for the quarter and 22% for the nine-month period compared to the prior year. This was driven by increased contract research services (notably from the German subsidiary Artemis Pharmaceuticals) and milestone revenues from collaborations with Genentech and Bristol-Myers Squibb.
- Expense Increases: Research and Development (R&D) expenses rose 27% for the quarter and 24% for the nine-month period, primarily due to expanded clinical trial activities for multiple compounds (XL784, XL880, XL647, XL820) and increased personnel costs.
- Unusual Items: The company recognized a one-time gain of $18.8 million from the sale of its plant trait business (Exelixis Plant Sciences) to Agrigenetics (a Dow Chemical subsidiary) in September 2007. This gain significantly reduced the reported net loss for the period.
- Financing Activity: In September 2007, Exelixis completed a public offering of 7 million shares of common stock, raising approximately $71.9 million in net proceeds.
Guidance, Outlook, and Risks
- Clinical Developments:
- XL784: A Phase 2 trial for diabetic nephropathy did not meet its primary endpoint of reducing proteinuria. However, subgroup analyses suggest potential benefit. GlaxoSmithKline (GSK) has 90 days to decide on further development.
- XL880: Interim Phase 2 data in papillary renal carcinoma showed anti-tumor activity. GSK has 90 days to decide on selection for further development.
- XL999: Development is focused on a new Phase 1 trial in NSCLC following a partial clinical hold due to cardiovascular adverse events in previous trials.
- Liquidity and Capital Resources: Management anticipates that current cash, marketable securities, and expected collaborator funding will support operations for at least 12 months. However, substantial additional funding will be required for future clinical development.
- Key Contingencies:
- SEI Repurchase Option: If GSK selects any of the SEI-licensed compounds (XL647, XL784, XL999) for development, Exelixis must exercise its option to repurchase all three compounds from SEI investors. The purchase price is $80 million plus 25% annual interest, payable in cash or stock.
- GSK Loan Covenants: The company must maintain working capital of at least $25 million and cash/investments of at least $50 million to comply with its loan agreement with GSK. As of September 30, 2007, the company was in compliance.
- Risks: Significant risks include the failure of clinical trials, the inability to raise additional capital, potential dilution from equity offerings, and the uncertainty of GSK's selection decisions regarding the pipeline.
Investor Verification Checklist
- Verify the status of GlaxoSmithKline's decision regarding the selection of XL784 and XL880 within the 90-day review period.
- Monitor the company's cash burn rate and the timing of any future capital raises required to maintain compliance with GSK loan covenants.
- Assess the financial impact of the potential repurchase of SEI assets, specifically the $80 million principal plus accrued interest obligation.
- Review the progress of the new Phase 1 trial for XL999 and any updates regarding the previous clinical hold.
- Confirm the sustainability of revenue streams from the Artemis Pharmaceuticals subsidiary and the new contract research agreement with Agrigenetics.